Home > Analytics > TORRENT PHARMACEUTICALS

TORRENT PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 500420     NSE : TORNTPHARM    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward
Pledged Shares : None or < 25%
Jun 24,2022
Price(EOD): β‚Ή 2,875.50
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: β‚Ή 48,653.46 Cr
Value of β‚Ή 1 Lac invested in TORRENT PHARMACEUTICALS
on Jun 27,2017 (price: β‚Ή 1,183.40)

β‚Ή 1 L

β‚Ή 2.43 L

1W : 4.1% 1M : -0.9% 1Y : -2.5%
COMMUNITY POLL
for TORRENT PHARMACEUTICALS
Please provide your vote to see the results
TORRENT PHARMACEUTICALS is part of below Screeners ↓
Best 1M Momentum Large Cap Stocks
Industry Peers & Returns1W1M1Y
TORRENT PHARMACEUTICALS 4.1% -0.9% -2.5%
SUN PHARMACEUTICAL INDUSTRIES 2.4% -8.5% 23.8%
DIVIS LABORATORIES 4.3% 6.7% -12.6%
DR REDDYS LABORATORIES 3.8% 0% -18.7%
CIPLA 0.8% -3.2% -2.4%
GLAND PHARMA 2.4% -7.3% -17.9%
PIRAMAL ENTERPRISES 3.9% -11% -33.4%
CADILA HEALTHCARE 5.7% -5.1% -45.1%
ALKEM LABORATORIES -3.6% -0.7% -3.5%

FUNDAMENTAL ANALYSIS OF TORRENT PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Mar2022, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF TORRENT PHARMACEUTICALS

 
Valuation Score
[As on : Jun 24,2022 ]

Ratio Consolidated
P/E
P/B
P/S
38.87
P/E Calculated based on EPS of 73.97
[ Mar2021 - Consolidated Results ]

8.34
P/B Calculated based on Book Value of 344.9
[ Mar2021 - Consolidated Results ]

5.72
P/S Calculated based on Revenues of 8510 Cr
[ TTM - Consolidated Results ]

Financial Ratios →

Insights πŸ’‘ There are potential 23% undervalued companies ! Discover More →

FAIR VALUE OF TORRENT PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
85%
223%
154%

Insights πŸ’‘ You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF TORRENT PHARMACEUTICALS


Insights πŸ’‘ TORNTPHARM is one of the top 10% companies with bullish price momentum currently! Discover More →

TORRENT PHARMACEUTICALS vs SENSEX


Insights πŸ’‘ You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF TORRENT PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.73
1.04
1.12
0.96
0.84
1.21
1.28
1.11
[Last Annual Data : Mar2021]
Financial Ratios →

PLEDGED PROMOTER SHARES OF TORRENT PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Mar2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF TORRENT PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
1.09%
4.28%
-124.37%
-147.39%
10.02%
-3.61%
-122.72%
-136.42%
QtrlyTrend
-2
Latest Qtr: Mar2022
Quarterly Result Analysis →


TORRENT PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 3.1% -1.8% -13%
S&P BSE 100 LARGECAP TMC 2.6% -2.1% -0.7%
S&P BSE 200 2.6% -1.9% -0.7%
S&P BSE LARGE MIDCAP 2.6% -1.9% -0.7%
S&P BSE 250 LARGEMIDCAP 2.5% -2% -0.8%
S&P BSE 500 2.5% -2% -1%
S&P BSE ALLCAP 2.5% -2% -0.8%
S&P BSE MID CAP 2.4% -0.1% -2.8%
S&P BSE MIDSMALLCAP 2% -1.4% -2%
NSE Indices1W1M1Y
NIFTY ALPHA LOW-VOLATILTY 30 3.5% -0.4% -3.5%
NIFTY HEALTHCARE 3.3% -1.7% -11.6%
NIFTY PHARMA 3.2% -2.9% -13.5%
NIFTY 100 EQUAL WEIGHT 2.9% -1.6% -2.9%
NIFTY 100 2.7% -2% -0.8%
NIFTY NEXT 50 2.7% -1.8% -5.3%
NIFTY 200 2.6% -2% -0.9%
NIFTY 500 2.5% -2% -1%
NIFTY LARGE MIDCAP 250 2.4% -1.7% -0.8%
NIFTY500 MULTICAP 50:25:25 2.3% -2% -1.3%

You may also like the below Video Courses


FAQ about TORRENT PHARMACEUTICALS


Is TORRENT PHARMACEUTICALS good for long term investment?

As on Jun 24,2022, the Fundamentals of TORRENT PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of TORRENT PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is TORRENT PHARMACEUTICALS UnderValued or OverValued?

As on Jun 24,2022, TORRENT PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of TORRENT PHARMACEUTICALS ?

As on Jun 24,2022, the Intrinsic Value of TORRENT PHARMACEUTICALS is Rs. 1,132.52 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,554.40
Fair Value [Median EV / Sales Model] : Rs. 889.59
Fair Value [Median Price / Sales Model] : Rs. 1,132.52
Median Fair Value of TORRENT PHARMACEUTICALS : Rs. 1,132.52

Is TORRENT PHARMACEUTICALS trading at a Premium or Discount?

As on Jun 24,2022, TORRENT PHARMACEUTICALS is trading at a Premium of 154% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z
ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z